Emanuele Zaffuto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7792272/publications.pdf

Version: 2024-02-01

			394421	3	377865
	58	1,343	19		34
	papers	citations	h-index		g-index
Ī					
	58	58	58		2164
	all docs	docs citations	times ranked		citing authors

#	Article	IF	Citations
1	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. European Urology, 2017, 72, 632-640.	1.9	165
2	Natural history of surgically treated high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 163.e7-163.e13.	1.6	101
3	Local Therapy Improves Survival in Metastatic Prostate Cancer. European Urology, 2017, 72, 118-124.	1.9	100
4	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. European Urology, 2019, 75, 319-328.	1.9	57
5	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. Journal of Urology, 2017, 197, 669-675.	0.4	55
6	The role of prostatic inflammation in the development and progression of benign and malignant diseases. Current Opinion in Urology, 2017, 27, 99-106.	1.8	54
7	Efficacy and safety of artificial urinary sphincter (AUS): Results of a large multiâ€institutional cohort of patients with midâ€term followâ€up. Neurourology and Urodynamics, 2019, 38, 710-718.	1.5	52
8	Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. Clinical Genitourinary Cancer, 2017, 15, e793-e800.	1.9	51
9	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. International Urology and Nephrology, 2018, 50, 71-78.	1.4	37
10	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	1.9	36
11	External Validation of the European Association of Urology Recommendations for Pelvic Lymph Node Dissection in Patients Treated with Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2014, 28, 416-423.	2.1	33
12	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. Prostate, 2017, 77, 686-693.	2.3	33
13	How can we expand active surveillance criteria in patients with lowâ€and intermediateâ€isk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. BJU International, 2018, 122, 823-830.	2.5	27
14	Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy. World Journal of Urology, 2019, 37, 221-234.	2.2	25
15	Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. World Journal of Urology, 2019, 37, 469-479.	2.2	25
16	Identifying candidates for superâ€extended staging pelvic lymph node dissection among patients with highâ€risk prostate cancer. BJU International, 2018, 121, 421-427.	2.5	24
17	How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. Journal of Endourology, 2014, 28, 792-800.	2.1	22
18	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Twoâ€Center Validation Study. Prostate, 2017, 77, 263-273.	2.3	22

#	Article	IF	CITATIONS
19	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2017, 72, 910-917.	1.9	21
20	Populationâ€Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate, 2017, 77, 105-113.	2.3	21
21	Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e7-461.e14.	1.6	19
22	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. European Urology Oncology, 2018, 1, 314-320.	5.4	19
23	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World Journal of Urology, 2018, 36, 639-644.	2.2	18
24	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e17-81.e24.	1.6	18
25	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Review of Clinical Pharmacology, 2018, 11, 425-438.	3.1	17
26	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.6	16
27	Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. International Journal of Urology, 2017, 24, 117-123.	1.0	16
28	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World Journal of Urology, 2018, 36, 1399-1407.	2.2	16
29	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 307.e9-307.e14.	1.6	16
30	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. World Journal of Urology, 2018, 36, 51-57.	2.2	16
31	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. European Urology Oncology, 2018, 1, 169-175.	5.4	16
32	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Canadian Urological Association Journal, 2018, 12, 173-80.	0.6	16
33	North American Populationâ€Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. Prostate, 2017, 77, 542-548.	2.3	15
34	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 528.e1-528.e5.	1.6	14
35	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. Clinical Genitourinary Cancer, 2017, 15, 67-71.	1.9	14
36	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. Journal of Geriatric Oncology, 2019, 10, 623-631.	1.0	14

3

#	Article	IF	CITATIONS
37	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. European Urology Oncology, 2019, 2, 456-463.	5.4	13
38	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1NOMO Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. European Urology Focus, 2018, 4, 972-977.	3.1	12
39	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. Prostate Cancer and Prostatic Diseases, 2018, 21, 386-393.	3.9	11
40	Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. World Journal of Urology, 2018, 36, 1417-1422.	2.2	11
41	Longâ€term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. BJU International, 2017, 120, 69-75.	2.5	10
42	New surgical approaches for clinically high-risk or metastatic prostate cancer. Expert Review of Anticancer Therapy, 2017, 17, 1013-1031.	2.4	9
43	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. Urologia Internationalis, 2019, 102, 269-276.	1.3	9
44	The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. World Journal of Urology, 2019, 37, 1127-1135.	2.2	9
45	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. European Urology Focus, 2021, 7, 1067-1074.	3.1	7
46	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. Clinical Genitourinary Cancer, 2019, 17, e541-e548.	1.9	6
47	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. European Urology Focus, 2019, 5, 545-549.	3.1	5
48	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. European Urology Focus, 2019, 5, 568-576.	3.1	5
49	Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. Urologia Internationalis, 2019, 102, 51-59.	1.3	4
50	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology and Oncology Research, 2019, 25, 979-986.	1.9	4
51	Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases. Translational Andrology and Urology, 2018, 7, 742-744.	1.4	3
52	Fascial Layers in Nerve Sparing Robot-Assisted Radical Prostatectomy. Urology Practice, 2014, 1, 86-91.	0.5	1
53	Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019:75:319–28. European Urology, 2019, 75. e98-e99.	1.9	1
54	Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?. Annals of Translational Medicine, 2016, 4, 291-291.	1.7	1

#	Article	IF	CITATIONS
55	Erectile Dysfunction and Penile Rehabilitation After Robot-Assisted Radical Prostatectomy. , 2018, , 455-462.		1
56	Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 659.e7-659.e12.	1.6	O
57	Pelvic Lymph Node Dissection for Prostate Cancer and Nomograms. , 2018, , 317-330.		О
58	Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319–28. European Urology, 2019, 75, e95.	1.9	0